Xilis, une start-up de technologie médicale de Durham, lève $70M ; Google Ventures et Duke Angels parmi les bailleurs de fonds

Date publiée:

Xilis, a startup founded by two professors at Duke University focusing on technology to boost precision health and oncology, has landed $70 million in new funding with Google Ventures among the backers.

The two-year-old company had previously raised close to $5 million.

“Our vision is to transform cancer care in diagnostics and reshape drug development by providing a technology for rapid therapeutic profiling,” said Xiling Shen, founder and CEO of Xilis, in Thursday’s announcement.. “The support provided by these world-class investors is an important milestone for our journey to transform cancer care and dramatically improve patient survival by enabling personalized precision oncology and bringing transformative medicines to patients faster and with higher success rates.”

Xilis se concentre sur ce qu'elle appelle la technologie MicroOrganoSphere (MOS) non seulement pour aider à l'administration de thérapies de précision aux patients atteints de cancer, mais également pour accélérer la découverte et le développement de médicaments.


QU'EST-CE QUE LE MOS ?

La technologie MicroOrganoSpher (MOS) exclusive de Xilis consiste en des tumeurs miniatures de patients qui capturent l'intégralité du microenvironnement et de l'hétérogénéité et fournissent une solution automatisée et évolutive. À l’aide d’algorithmes basés sur le MOS et l’IA, Xilis développe un Xilis Response Score™ pour la clinique, permettant aux oncologues de prendre des décisions de traitement éclairées et en temps opportun. De plus, la technologie MOS accélère le développement et les essais cliniques de médicaments contre le cancer en permettant l'analyse de microenvironnements tumoraux authentiques, une modélisation préclinique à haut débit et des capacités de sélection clinique des patients.


Mubadala Capital led the round.

The Duke Angel Network also participated.

LSP in Europe, Catalio Capital Management and previous nvestors Felicis Ventures, Two Sigma Ventures, Pear VC, KdT Ventures, and Alix Ventures also joined the funding.

Shen, David Hsu and Hans Clevers founded the company. Clevers invented the “organoid” technology and also is a venture partner at LSP. Shen and Hsu teach at Duke University.

“Since my lab invented organoids a dozen years ago, we provided proof-of-concept for many applications, yet the technology remained slow, complex, and expensive,” Clevers said in a statement. ” Together with LSP, I have been looking for enabling technology to unlock the full potential, and Dr. Shen and Dr. Hsu’s invention of the MOS technology has torn down those hurdles and will accelerate its use both in the clinic and for drug discovery and development.”

The funds will be used “to further advance Xilis’ proprietary MOS technology, expand its AI-driven capabilities, fund clinical studies for diagnostic development, and validate the use of MOS technology with biopharma partners,” the company said.

“Genetic approaches to cancer diagnostics continue to be impactful, and Xilis is creating meaningful pathways for its Precision Oncology Platform to improve cancer care for a broader set of patients,” said Google Ventures (GV) Managing Partner Krishna Yeshwant. “Xilis brings together experts in the fields of organoid development and precision medicine, and I’m excited to work with this impressive team as they continue to develop a breakthrough approach.”

Source primaire: WRAL TechWire